Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 31


Heat shock proteins (HSPs) in the homeostasis of regulatory T cells (Tregs).

Koliński T, Marek-Trzonkowska N, Trzonkowski P, Siebert J.

Cent Eur J Immunol. 2016;41(3):317-323. Epub 2016 Oct 25. Review.


The Role of the Membrane-Initiated Heat Shock Response in Cancer.

Bromberg Z, Weiss Y.

Front Mol Biosci. 2016 Apr 27;3:12. doi: 10.3389/fmolb.2016.00012. eCollection 2016. Review.


Destabilizing RET in targeted treatment of thyroid cancers.

Gild ML, Bullock M, Pon CK, Robinson BG, Clifton-Bligh RJ.

Endocr Connect. 2016 Jan;5(1):10-9. doi: 10.1530/EC-15-0098. Epub 2015 Nov 16.


Hsp90: A New Player in DNA Repair?

Pennisi R, Ascenzi P, di Masi A.

Biomolecules. 2015 Oct 16;5(4):2589-618. doi: 10.3390/biom5042589. Review. Erratum in: Biomolecules. 2016 Oct 18;6(4):.


The HSP90 inhibitor ganetespib: A potential effective agent for Acute Myeloid Leukemia in combination with cytarabine.

Lazenby M, Hills R, Burnett AK, Zabkiewicz J.

Leuk Res. 2015 Jun;39(6):617-24. doi: 10.1016/j.leukres.2015.03.016. Epub 2015 Mar 30.


The crossroads between cancer stem cells and aging.

Santos Franco S, Raveh-Amit H, Kobolák J, Alqahtani MH, Mobasheri A, Dinnyes A.

BMC Cancer. 2015;15 Suppl 1:S1. doi: 10.1186/1471-2407-15-S1-S1. Epub 2015 Jan 15. Review.


Heat shock protein-90 inhibitors enhance antigen expression on melanomas and increase T cell recognition of tumor cells.

Haggerty TJ, Dunn IS, Rose LB, Newton EE, Pandolfi F, Kurnick JT.

PLoS One. 2014 Dec 12;9(12):e114506. doi: 10.1371/journal.pone.0114506. eCollection 2014.


A bombesin-shepherdin radioconjugate designed for combined extra- and intracellular targeting.

Fischer CA, Vomstein S, Mindt TL.

Pharmaceuticals (Basel). 2014 May 27;7(6):662-75. doi: 10.3390/ph7060662.


The HSP90 inhibitor ganetespib has chemosensitizer and radiosensitizer activity in colorectal cancer.

He S, Smith DL, Sequeira M, Sang J, Bates RC, Proia DA.

Invest New Drugs. 2014 Aug;32(4):577-86. doi: 10.1007/s10637-014-0095-4. Epub 2014 Apr 1.


Radioprotective effects of oral 17-dimethylaminoethylamino-17-demethoxygeldanamycin in mice: bone marrow and small intestine.

Lu X, Nurmemet D, Bolduc DL, Elliott TB, Kiang JG.

Cell Biosci. 2013 Sep 16;3(1):36. doi: 10.1186/2045-3701-3-36.


HPLC method development, validation and impurity characterization for an antitumor Hsp90 inhibitor-PU-H71 (NSC 750424).

Liu M, Wang J, Wu X, Wang E, Baptista D, Scott B, Liu P.

J Pharm Biomed Anal. 2014 Feb;89:34-41. doi: 10.1016/j.jpba.2013.10.021. Epub 2013 Oct 24.


A novel therapeutic strategy for the treatment of glioma, combining chemical and molecular targeting of hsp90a.

Mehta A, Shervington L, Munje C, Shervington A.

Cancers (Basel). 2011 Dec 8;3(4):4228-44. doi: 10.3390/cancers3044228.


A novel Hsp90 inhibitor AT13387 induces senescence in EBV-positive nasopharyngeal carcinoma cells and suppresses tumor formation.

Chan KC, Ting CM, Chan PS, Lo MC, Lo KW, Curry JE, Smyth T, Lee AW, Ng WT, Tsao GS, Wong RN, Lung ML, Mak NK.

Mol Cancer. 2013 Oct 24;12(1):128. doi: 10.1186/1476-4598-12-128.


Targeted inhibition of Hsp90 by ganetespib is effective across a broad spectrum of breast cancer subtypes.

Friedland JC, Smith DL, Sang J, Acquaviva J, He S, Zhang C, Proia DA.

Invest New Drugs. 2014 Feb;32(1):14-24. doi: 10.1007/s10637-013-9971-6. Epub 2013 May 18.


Inhibition of gastric tumor growth by a novel Hsp90 inhibitor.

Lu C, Liu D, Jin J, Deokar H, Zhang Y, Buolamwini JK, Yu X, Yan C, Chen X.

Biochem Pharmacol. 2013 May 1;85(9):1246-56. doi: 10.1016/j.bcp.2013.02.003. Epub 2013 Feb 13.


Hsp90, an unlikely ally in the war on cancer.

Barrott JJ, Haystead TA.

FEBS J. 2013 Mar;280(6):1381-96. doi: 10.1111/febs.12147. Epub 2013 Feb 24. Review.


Protein interactions, post-translational modifications and topologies in human cells.

Chavez JD, Weisbrod CR, Zheng C, Eng JK, Bruce JE.

Mol Cell Proteomics. 2013 May;12(5):1451-67. doi: 10.1074/mcp.M112.024497. Epub 2013 Jan 25.


Potent activity of the Hsp90 inhibitor ganetespib in prostate cancer cells irrespective of androgen receptor status or variant receptor expression.

He S, Zhang C, Shafi AA, Sequeira M, Acquaviva J, Friedland JC, Sang J, Smith DL, Weigel NL, Wada Y, Proia DA.

Int J Oncol. 2013 Jan;42(1):35-43. doi: 10.3892/ijo.2012.1698. Epub 2012 Nov 14.


Development of a Grp94 inhibitor.

Duerfeldt AS, Peterson LB, Maynard JC, Ng CL, Eletto D, Ostrovsky O, Shinogle HE, Moore DS, Argon Y, Nicchitta CV, Blagg BS.

J Am Chem Soc. 2012 Jun 13;134(23):9796-804. doi: 10.1021/ja303477g. Epub 2012 May 29.


An Hsp90 modulator that exhibits a unique mechanistic profile.

Ramsey DM, McConnell JR, Alexander LD, Tanaka KW, Vera CM, McAlpine SR.

Bioorg Med Chem Lett. 2012 May 1;22(9):3287-90. doi: 10.1016/j.bmcl.2012.03.012. Epub 2012 Mar 11.

Supplemental Content

Support Center